Sanofi and Teva to Collaborate on Treatment for Inflammatory Bowel Disease

Sanofi and Teva Pharmaceuticals have entered into a collaboration to co-develop and co-commercialize TEV’574, currently in Phase 2b clinical trials for the treatment of ulcerative colitis and Crohn’s disease, two types of inflammatory bowel disease (IBD) characterized by chronic inflammation of the gastrointestinal tract. An estimated 10 million people worldwide live with IBD.

According to Sanofi CEO Paul Hudson, “Anti-TL1As are a promising class of therapies, and we believe that TEV’574 could emerge as a best-in-class option for people living with serious gastrointestinal diseases. This collaboration strengthens our commitment to advancing innovative treatment options for inflammatory conditions with a high unmet need and bolsters our goal to be an industry leader in immunology.”

Under the terms of the new collaboration agreement, Teva will receive an upfront payment of $500 million and up to $1 billion in development and launch milestones. Each company will equally share the development costs globally and net profits and losses in major markets, with other markets subject to a royalty arrangement and Sanofi will lead the development of the Phase 3 program. Teva will lead commercialization of the product in Europe, Israel and specified other countries, and Sanofi will lead commercialization in North America, Japan, other parts of Asia and the rest of the world. The transaction will become effective after customary closing conditions are met. Initial program results are expected to be available in 2024. (Source: Sanofi Website, 04 October, 2023)